Moderna Named a Top Employer by Science for Eleventh Consecutive Year

Rhea-AI Summary

Moderna (NASDAQ:MRNA) was named a top employer in the global biopharmaceutical industry by Science and Science Careers in the 2025 Top Employers Survey for the eleventh consecutive year. The recognition cites Moderna's focus on innovation, employee-centered culture and investments in advanced manufacturing hubs in Australia, Canada and the United Kingdom. In 2025 Moderna received approval for its third product, mNEXSPIKE, a COVID-19 vaccine for adults 65+ and ages 12–64 with specified risk factors.

The survey was based on ~5,500 completed responses, primarily from North America, Europe and Asia/Pacific Rim.

Positive

• Ranked top employer for 11 consecutive years
• mNEXSPIKE received regulatory approval in 2025
• Investments in advanced manufacturing hubs in Australia, Canada, UK
• Survey based on ~5,500 respondent evaluations

Negative

• None.

CAMBRIDGE, MA / ACCESS Newswire / October 23, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as a top employer in the global biopharmaceutical industry in Science and Science Careers' 2025 Top Employers Survey for the eleventh consecutive year. Moderna was recognized for its commitment to continuous innovation and a culture that reflects the values of its employees.

"We are honored to be recognized by Science as a top employer, with this year marking the eleventh consecutive year we have been named to this important list," said Stéphane Bancel, Chief Executive Officer of Moderna. "Our team continues to execute our strategy, advancing our pipeline of mRNA medicines and staying focused on our commitment to patients. I am proud that Moderna remains a company where our team members can build purposeful careers."

In 2025, Moderna received approval for its third product, mNEXSPIKE®, a new vaccine against COVID-19 for use in all adults 65 and older and individuals aged 12-64 years with at least one or more underlying risk factors. As its product portfolio grows, Moderna has continued to invest in its global network of advanced manufacturing hubs in Australia, Canada and the United Kingdom, which strengthen pandemic readiness by maximizing geographic coverage and minimizing response times. As part of Moderna's ongoing commitment to social responsibility, the Company also marked the third anniversary of the Moderna Charitable Foundation and issued its fourth annual Impacting Human Health Report.

"At Moderna, we are bringing together people and technology to change what's possible in medicine," said Tracey Franklin, Chief People and Digital Technology Officer of Moderna. "Our teams are constantly adapting, learning and applying new tools, like AI and robotics, in ways to drive innovation and create meaningful impact for years to come."

For more than 20 years, Science has surveyed its readership to identify and celebrate the top 20 pharmaceutical and biotechnology companies with the best reputation as employers. The 2025 survey's findings are based on approximately 5,500 completed surveys from readers of Science, and other survey invitees. A vast majority of the survey participants came from North America (66%), Europe (20%) and Asia/Pacific Rim (9%). Most (97%) of the respondents worked in biotechnology, biopharmaceutical and pharmaceutical companies.

For the complete feature along with individual company rankings, please visit: https://www.science.org/content/article/2025-s-top-employers-innovation-ai-and-policy-biotech-pharma

About Moderna

Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including pioneering work on COVID-19 vaccines.

Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.

Moderna Contacts

Media:
Chris Ridley
Head, Global Media Relations
+1 617-800-3651
Chris.Ridley@modernatx.com

Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
Lavina.Talukdar@modernatx.com

SOURCE: Moderna, Inc.

View the original press release on ACCESS Newswire

FAQ

What recognition did Moderna (MRNA) receive in the 2025 Science Top Employers Survey?

Moderna was ranked as a top employer in the global biopharmaceutical industry for the eleventh consecutive year.

What product approval did Moderna (MRNA) announce in 2025?

Moderna received approval in 2025 for mNEXSPIKE, a COVID-19 vaccine for adults 65+ and ages 12–64 with at least one risk factor.

How large was the Science 2025 Top Employers Survey used to rank Moderna (MRNA)?

The ranking was based on approximately 5,500 completed surveys from Science readers and invitees.

What manufacturing investments did Moderna (MRNA) highlight in the announcement?

Moderna said it has continued investing in advanced manufacturing hubs in Australia, Canada and the United Kingdom to strengthen pandemic readiness.

How does Moderna (MRNA) describe its workplace culture in the 2025 announcement?

Moderna described its culture as focused on continuous innovation, employee values and enabling purposeful careers.